Autoimmunity alternative

Why Step Pharma thinks CTPS1 could become a hot autoimmune target

Inhibiting the nucleotide biosynthetic pathway in autoimmune diseases is one way to avoid the risks of broad immunosuppression, but the marketed compounds have serious side effects of their own. Step Pharma is pursuing a safer alternative by going after a target on the pathway, CTPS1, that is up-regulated only on active immune cells.

CTPS1 converts uridine 5’-triphosphate (UTP) to cytidine 5’-triphosphate (CTP), a step required to

Read the full 656 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers